Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses

Clinical Drug Investigation

Volumn 24, Issue 1, 2004, Pages 49-53

  Kurowski, Michael ^a   Oo, Charles ^b   Wiltshire, Hugh ^c   Barrett, Joanne ^c  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b HOFFMANN LA ROCHE INC   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; INFLUENZA VIRUS; MALE; MAXILLA SINUSITIS; MIDDLE EAR; PREOPERATIVE CARE; PRIORITY JOURNAL; SEROUS OTITIS MEDIA; SURGICAL DRAINAGE; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 1042279482     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424010-00006     Document Type: Article

References (22)

1. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998; 42: 640-6
2. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 219-64
3. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology. Philadelphia (PA): Lippincott-Raven Publishers, 1996: 1397-445
4. Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilization associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000; 19: 834-42
5. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980; 112: 798-813
6. Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalisations as a measure of impact of epidemic influenza. Am J Epidemiol 1985; 122: 468-76
7. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283: 1016-24
8. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999; 340: 260-4
9. Buchman CA, Fregien N. Influenza A virus infection of human middle ear cells in vitro. Laryngoscope 2000; 110: 1739-44
10. Cundy KC, Eisenberg G, Bidgood A, et al. Enhanced delivery of the novel influenza neuraminidase inhibitor GS4071 to rat lung after oral administration of the prodrug GS4104 [abstract A-122]. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28-Oct 1; Toronto
11. Eisenberg EJ, Bidgood A, Cundy KC. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Agents Chemother 1997; 41: 1949-52
12. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37: 471-84
13. Wiltshire HR, Muir J, Lambkin R, et al. Distribution pattern of GS4071, a novel influenza neuraminidase inhibitor, following oral administration of its prodrug GS4104 in the ferret model [abstract]. Meeting of the European Society of Clinical Virology; 1998 Aug 30-Sep 2; Hamburg
14. Mendel DB, Roberts NA. In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors. Curr Opin Infect Dis 1998; 11: 727-32
15. Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802. an anti-influenza drug, and its pro-drug, oseltamivir in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 2000; 745: 373-88
16. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000; 355: 1845-50
17. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20: 127-33
18. Reisinger K, Winther B, Hayden F, et al. Oral oseltamivir reduces the risk and duration of acute otitis media in preschool children [abstract]. World Conference of Family Doctors (WONCA); May 13-17 2001, Durban, South Africa
19. Garrison MW, Malone CL, Eiland J, et al. Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against haemophilus influenzae using an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis 1997; 27: 139-45
20. Jossart GH, Erdmann GR, Steury JC, et al. Effects of pH and protein binding on middle ear antimicrobial drug penetration may explain acute otitis media treatment failures. In: Lim DJ, Bluestone CD, Klein JO, et al., editors. Recent advances in otitis media: proceedings of the Fifth International Symposium. Burlington (ON): Decker, 1993: 446-9
21. Karnad DR, Mhaisekar DG, Moralwar KV. Respiratory mucus pH in tracheostomized intensive care unit patients: effects of colonization and pneumonia. Crit Care Med 1990; 18: 699-701
22. Jossart GH, Canafax DM, Erdmann GR, et al. Effect of Streptococcus pneumoniae and influenza A virus on middle ear antimicrobial pharmacokinetics in experimental otitis media. Pharm Res 1994; 11: 860-4